“Obviously, we remain very confident that we will close Seagen towards the end of this year, beginning next year.”

In context

“this product as planned. Operator: Next, we have Geoff Meacham with Bank of America. Geoff Meacham: Just have a couple of quick ones. First, I know Seagen obviously hasn't closed yet. But there's all the emphasis on the ADCs from ESMO. Does it affect how you guys prioritize the pipeline or maybe investments you could make today commercially? And the second question on danu, Mikael, I know a lot has been asked on the upcoming data, but from a commercial perspective, like where do you see the bigger opportunities for differentiation and metabolic? Is it really just oral administration in obesity? Or do you guys look more aggressively at related indications like cardio, renal, et cetera. Albert Bourla: Chris, do you want to take a question about the Seagen and the pipeline? Chris Boshoff: Obviously, we remain very confident that we will close Seagen towards the end of this year, beginning next year. As you pointed out, there's a significant interest now in ADCs because of the potential that they could replace most of the chemotherapeutics in the future for most cancer types. Seagen obviously has a significant track record with both the current approved ADCs from the laboratories and, as you've seen, three potential registration phase trials just read out and passed up to Kaiser [indiscernible] but also with the small molecule to Kaiser. They recently started two Phase 3 studies, one with tisotumab vedotin in combination with pembrolizumab in advanced metastatic, HER2 positive or HER2 low bladder cancer. This is a program that we're very excited about. Already tisotumab received previously breakthrough therapeutic innovation in the US. And they're also just about to start another Ph”